MedTrace Logo

Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine

NCT02176018 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2018-04-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and effectiveness of daily dextromethorphan/quinidine (Nuedexta) in reducing the frequency and progression of episodic migraine.

Conditions

  • Episodic Migraine

Interventions

DRUG

Dextromethorphan and quinidine

DRUG

Placebo

Sponsors & Collaborators

  • Avanir Pharmaceuticals

    collaborator INDUSTRY

  • Cady, Roger, M.D.

    lead INDIV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2017-02-28
Completion
2017-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02176018 on ClinicalTrials.gov